CELLDEX THERAPEUTICS INC (CLDX) Stock Price & Overview
NASDAQ:CLDX • US15117B2025
Current stock price
The current stock price of CLDX is 31.06 USD. Today CLDX is down by -0.64%. In the past month the price increased by 5.79%. In the past year, price increased by 96.83%.
CLDX Key Statistics
- Market Cap
- 2.068B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.89
- Dividend Yield
- N/A
CLDX Stock Performance
CLDX Stock Chart
CLDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLDX. When comparing the yearly performance of all stocks, CLDX is one of the better performing stocks in the market, outperforming 90.53% of all stocks.
CLDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLDX. While CLDX has a great health rating, there are worries on its profitability.
CLDX Earnings
On February 25, 2026 CLDX reported an EPS of -1.22 and a revenue of 121.00K. The company missed EPS expectations (-18.58% surprise) and missed revenue expectations (-91.97% surprise).
CLDX Forecast & Estimates
22 analysts have analysed CLDX and the average price target is 55.42 USD. This implies a price increase of 78.43% is expected in the next year compared to the current price of 31.06.
For the next year, analysts expect an EPS growth of -22.28% and a revenue growth 27.53% for CLDX
CLDX Groups
Sector & Classification
CLDX Financial Highlights
Over the last trailing twelve months CLDX reported a non-GAAP Earnings per Share(EPS) of -3.89. The EPS decreased by -58.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.38% | ||
| ROE | -49.08% | ||
| Debt/Equity | 0 |
CLDX Ownership
CLDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLDX
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 198 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Company Info
IPO: 1986-05-15
CELLDEX THERAPEUTICS INC
53 Frontage Road, Suite 220
Hampton NEW JERSEY 08827 US
CEO: Anthony S. Marucci
Employees: 186
Phone: 13026587581
CELLDEX THERAPEUTICS INC / CLDX FAQ
Can you describe the business of CELLDEX THERAPEUTICS INC?
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 198 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Can you provide the latest stock price for CELLDEX THERAPEUTICS INC?
The current stock price of CLDX is 31.06 USD. The price decreased by -0.64% in the last trading session.
Does CELLDEX THERAPEUTICS INC pay dividends?
CLDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLDX stock?
CLDX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of CLDX stock?
CELLDEX THERAPEUTICS INC (CLDX) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of CELLDEX THERAPEUTICS INC (CLDX)?
CELLDEX THERAPEUTICS INC (CLDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.89).
Can you provide the growth outlook for CELLDEX THERAPEUTICS INC?
The Revenue of CELLDEX THERAPEUTICS INC (CLDX) is expected to grow by 27.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.